EATG » News

Open letter: UN General Assembly High Level Meeting on the fight against Tuberculosis

Few weeks before the UN General Assembly High Level Meeting on the fight against Tuberculosis, the EATG issues an open letter: 'As negotiations on the final declaration are now being…

ESTICOM: First from a series of community reports from EMIS 2017 is now online

A week ago the EATG co-chaired the satellite symposium "European surveys and trainings to improve MSM community health (ESTICOM)" at the 22nd International AIDS conference.  During this session we had…

The EATG welcomes the European Court of Justice decision to invalidate the patent extension of Truvada

Amsterdam, 26 July 2018   The European AIDS Treatment Group welcomes the landmark decision of the European Court of Justice confirming the invalidity of the patent extension (Supplementary Protection Certificate)…

EATG at the 22nd International AIDS conference: Catch up with the evidence and give our communities the services we need

Amsterdam, 23 July 2018   As an organisation led by people living with HIV/AIDS across Europe and Central Asia, working together with the several affected communities in the last 25…

AIDS 2018: Addressing research gaps identified by women living with HIV in Europe and Central Asia

We are pleased to invite you to join a side-meeting at the AIDS 2018 conference that will bring together community, clinicians and researchers to discuss research gaps related to women…

AIDS 2018: The programme of the European Civil Society Forum booth in the Global Village is now online

The EATG and AIDS Action Europe are co-hosting the European Civil Society Forum (booth 618) at the Global Village of the 22nd International AIDS Conference in Amsterdam. Organisations and activists…

Ageing with HIV conference outcomes: read watch and register to discuss

The EATG organised a conference titled ‘New challenges and unmet needs of people living and ageing with HIV/AIDS aged 18-50, Quality of Life and Preventive Healthcare’ from 3 to 6…

EATG’s new term as a member of the Civil Society Forum on Drugs (2018-2021)

This week the European AIDS Treatment Group participated in the first meeting of the new 3-year term of the Civil Society Forum on Drugs that took place in Brussels. The CSFD…

What is on the minds of PLHIV in Europe in terms of their long term health?

Results: Long term health perspectives of people living with HIV in Europe   The EATG in collaboration with Volle Maan Communicatie Bureau conducted a study titled ‘Long term health perspectives…

EHVA: a clinical trial for therapeutic vaccination for HIV is about to start

Today and tomorrow EATG is attending the European HIV Vaccine Alliance (EHVA) consortium meeting in Barcelona. The EATG is one of the 39 partners of the consortium that aims to develop…

Position on scaling up HIV self-testing and self-sampling

Just published - an opinion piece on scaling up HIV self-testing and self-sampling, by the HIV in Europe Initiative (a European civil society, policy makers, health professionals and public health…

A more social Europe needs a more robust Health Programme

The EU Civil Society Forum on HIV, TB and Hepatitis, gathering leading civil society organisations at the national and regional level in the EU and neighbouring countries, welcomes with caution the…

EATG 2017 annual report is out now

2017 was the year that marked 25 exciting years of HIV/AIDS activism for the European AIDS Treatment Group. A year working towards achieving our goals and objectives is condensed in…

Call for organisations and activists to present at the European NGO booth (world AIDS 2018 conference)

We are happy to invite organisations and activists in Europe and Central Asia to present, discuss, share and learn at European NGO booth at the world AIDS 2018 Amsterdam conference.…

EATG launches a report on access to HCV-related services in prison settings in Europe

Today, the European AIDS Treatment Group launches a report along with recommendations on access to HCV-related services in prison settings in Europe. At the same time, a pilot Spring European…

Civil society organizations come forth with a Joint Statement in advance of the 39th meeting of the Global Fund Board

With a joint statement addressed to the Global Fund, more than 40 international, regional and national organizations have voiced their deep concerns regarding Global Fund's eligibility policy and the limitations…

Ageing with HIV: New challenges and unmet needs of people aged 18 – 50 years living and ageing with HIV/AIDS (3-6 May 2018, Kiev)

The closing meeting from the third phase of the Ageing with HIV project is kicking off tomorrow in Kiev and will run until Sunday. We are excited to welcome 94…

Webinar: Results of the METRODORA research on the involvement of women in HIV clinical trials

EATG will host a webinar on the Results of the METRODORA research on the involvement of women in HIV clinical trials on Wednesday, 02 May 2018, 13:00 – 14:00 CEST…

Webinar: Introduction to medicine research and development

EATG will host a webinar, Introduction to medicine research and development, on Thursday, 26 April 2018, 18:00 – 19:00 CEST (Brussels, Berlin, Paris time). The webinar will be led by…

Positive Stories: the voices of women living with HIV across Europe

The EATG has launched a new initiative aiming to give women living with or affected by HIV a platform to make their voices heard. Positive Stories is an empowerment tool…

Is self-testing with the rapid HIV test reliable?

Researchers reviewed previous studies to address concerns regarding the reliability of a self-administered rapid HIV test. HIV self-testing is highly accepted among many groups and is a useful way to…

An aspirin a day may keep HIV away, study finds

An affordable, globally available drug – low-dose Aspirin – shows promise as a new approach to preventing HIV transmission, a University of Manitoba study has found. HIV infection rates remain…

New antibody analysis accelerates rational vaccine design

Scripps Research study illuminates humoral immune response to experimental vaccines. A team at Scripps Research has come up with a faster way to analyze the outcome of experimental vaccines against…

Study demonstrates mortality benefit of Xpert TB assay in HIV patients

Patients newly diagnosed with advanced HIV in Malawi who were screened for tuberculosis with the Xpert MTB/RIF assay had significantly lower rates of 12-month, all-cause mortality than patients who were…

EMA updates on Viekirax and Victrelis

Viekirax (ombitasvir/paritaprevir/ritonavir) - change to existing contraindication Contraindicated in patients with moderate hepatic impairment Read more here.   ******************* Victrelis (boceprevir) - withdrawal of marketing authorization The marketing authorisation for…

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound

China patent challenge compels Gilead to withdraw key patent claims on sofosbuvir base compound, opening life-saving hepatitis C treatment access for millions I-MAK’s successful patent challenge against Gilead cracks open…

AIDS 2018: People with HIV receiving methadone and HIV drugs spend less time with detectable viral load

People on methadone maintenance treatment spent less time with a detectable viral load above 1500 copies/ml, potentially reducing the risk of HIV transmission, a study presented at last month’s 22nd…

Youth voices count and safe spaces do too

A global coalition of more than 80 youth organizations working on HIV (the PACT), and Youth Voices Count (YVC) launched a poll to get a sense of what young people…

EMA: working for every patient in Europe

A short video to explain who EMA is and what it does The European Medicines Agency (EMA) ensures that medicines available in the European Economic Area (EEA) are safe, effective…

58% of those with diagnosed HIV in the US were virally suppressed in 2014

This is according to a CDC analysis of surveillance records from 37 states and Washington, DC. About 58 percent of U.S. residents living with diagnosed HIV had a fully suppressed…

Hundreds prescribed PrEP in New Zealand

Hundreds of prescriptions for a "revolutionary" HIV-prevention drug have been approved in the first few months of it being more widely available. Pharmac expanded access to Truvada in March. In…

Superdrug first large UK retailer to sell HIV self-testing kits

Kits 99.7% accurate and take 15 minutes – but £33.99 cost could be out of reach of many Superdrug has become the first large high street British retailer to sell…

CATIE: July/August 2018 issue of TreatmentUpdate now online

TreatmentUpdate is CATIE’s flagship digest on cutting-edge developments in HIV and hepatitis C research and treatment. TreatmentUpdate 228: Anti-HIV agents and co-morbidities, July/August 2018 issue is available at: http://www.catie.ca/en/treatmentupdate/treatmentupdate-228

Cocrystal Pharma commences Phase 2a study evaluating CC-31244 for the treatment of HCV

Cocrystal Pharma commences enrollment and initiates patient dosing in Phase 2a study evaluating CC-31244 for the treatment of HCV - Topline results from Phase 2a study expected to be announced…

Eiger Biopharmaceuticals enrolls first patient in trial for hepatitis D therapy

Eiger BioPharmaceuticals announced the first patient enrollment in its phase 2 study of combination interferon lambda with ritonavir-boosted lonafarnib, according to a press release. “Eiger is developing lonafarnib-based regimens alone…

Enhanced waitlist outcomes in transplant candidates willing to accept HCV+ kidneys

The willingness of hepatitis C RNA-positive (RNA+) waitlisted candidates to accept a kidney from a hepatitis C seropositive donor (HCVD+) was found to have benefits, including an increase in the…

FDA updates hepatitis C drug labeling to include new clinical data

The FDA has approved updates to the labeling for hepatitis C virus (HCV) drug glecaprevir and pibrentasvir (Mavyret) to include new data from 2 clinical studies, according to a press…

Scientists shed new light on hepatitis B virus origins

New insight on the origins and global spread of two classes of the hepatitis B virus likely reflect the impact of prehistoric and more recent human migrations and other activities…

Scientists say genetically modified rice can prevent HIV

Researchers say a new genetically modified rice can prevent infections of HIV, the virus responsible for the disease AIDS. The researchers recently published their findings in a study in the journal Proceedings of the National…

Early cART initiation improves dental outcomes in kids

Children who are perinatally infected with HIV have better dental and periodontal outcomes, including less tooth decay and bleeding, when they begin combination ART and integrase or protease inhibitors before…